Cite

    Barbara Eichhorst et al.. “First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.” Lancet oncology, vol. 17, no. 7, n.d., pp. 928–942. http://access.bl.uk/ark:/81055/vdc_100033761042.0x000018